[46] identified TPM3‐NTRK1 fusions as rare but recurrent events in colorectal cancer, linked to constitutive TRKA activation and oncogenesis, suggesting TRK inhibitors as therapeutic targets. This evidence concerns the gene NTRK1 and colorectal cancer.